An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This trial is an open-label, multi-centre, single arm extension for the 000006 trial in
Chinese patients with prostate cancer. Eligible patients will receive monthly (28-day
intervals) maintenance doses of 80 mg (20 mg/mL) degarelix administered by subcutaneous
(s.c.) injection for a period of 2 years from first visit in this extension trial. Patients,
who received goserelin treatment in the main trial, will get a degarelix starting dose (240
mg; 40 mg/mL) at the first visit and continue on degarelix treatment. The purpose of this
2-year extension trial is to collect long-term safety and tolerability data for the one-month
dosing regimen.